Clinical Trial Update: Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating single-dose MK-3866 in participants with hepatic impairment; the trial is terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency

Drugs mentioned

• MK-3866

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatic Insufficiency, Antibacterial Agents | Phase 1 | Status: TERMINATED | Results posted: 2019-11-13